107 results about "Lipid bilayer" patented technology

The invention relates to the technical field of biology, in particular to silymarin inclusion compound lipidosome and a preparation method and application thereof. The silymarin inclusion compound liposome is prepared from the following components in parts by weight: 10 to 48 parts of silymarin, 10 to 53 parts of phospholipid, 5 to 10 parts of Arabic gum and 25 to 70 parts of cyclodextrin. According to the invention, cyclodextrin and phospholipid are combined to form a double-drug-loading structure; on the basis, Arabic gum is used as a film-forming agent to form a protective film on the surface of the liposome, so that the stability of the system is further improved; the silymarin inclusion compound is encapsulated in a water phase in the liposome, and meanwhile, part of free silymarin is encapsulated in a lipid bilayer. According to the structure, the solubility and the encapsulation efficiency of the silymarin are remarkably improved, the liposome stability is enhanced, the drug release is effectively controlled, and the silymarin inclusion compound lipid is simple in preparation process and suitable for industrial production.

Embodiments of the present invention include methods of targeting acidosis (low pH) within the tumor microenvironment (TME) through the use of cathodic electrochemical reactions (CER). Low pH is oncogenic by supporting immunosuppression. Electrochemical reactions create local pH effects when a current passes through an electrolytic substrate such as biological tissue. Electrolysis has been used with electroporation (destabilization of the lipid bilayer via an applied electric potential) to increase cell death areas. However, the regulated increase of pH through only the cathode electrode has been ignored as a possible method to alleviate TME acidosis, which could provide substantial immunotherapeutic benefits. Here, ex vivo modeling shows that CERs can intentionally elevate pH to an anti-tumor level and that increased alkalinity promotes activation of naïve macrophages. Embodiments of the invention include pairing CER treatment protocols with existing electric field-based cancer therapies or use as a stand-alone therapy.

The invention discloses a recombinant collagen composite nano-liposome as well as a preparation method and application thereof. The composite nano-liposome provided by the invention comprises a liposome which is provided with a closed lipid bilayer molecular layer and a content encapsulated in the closed lipid bilayer molecular layer; and a polyquaternium-51 layer that encapsulates the liposome. A supramolecular assembly, phospholipid wrapping and polyquaternium-51 protective layer is formed on the surface of the protein through a hierarchical wrapping technology, and multiple technologies are superposed, so that the stability and the transdermal absorption effect of the protein and the lipidosome are remarkably improved.

The present application relates to a kind of robecoxib liposome and its preparation method and application, the preparation raw material of the robecoxib liposome includes phospholipid, cholesterol and robecoxib, and the robecoxib is encapsulated in lipid bilayer, and the robecoxib liposome of the present application improves the solubility of robecoxib, and has higher encapsulation efficiency and drug loading.

The application provides a paclitaxel liposome injection and a preparation method thereof, and belongs to the technical field of pharmaceutical preparations. The injection is prepared from the following injection-grade raw and auxiliary materials: paclitaxel, phospholipid, cholesterol, gamma-aminobutyric acid, potassium lactate, a buffer, a freeze-drying protective agent and water for injection. The gamma-aminobutyric acid and the potassium lactate are simultaneously added as the liposome membrane stabilizer, the two synergistically act, the compactness and the stability of the lipid bilayer are significantly enhanced, the paclitaxel encapsulation rate is improved, the drug leakage rate is reduced, and the long-term storage stability of the preparation is improved.

This invention relates to the field of biomedicine, and more particularly to a hair follicle-targeted delivery system and a hair growth and anti-hair loss cosmetic. The hair follicle-targeted delivery system comprises: a lipid nanoparticle core loaded with bioactive ingredients having hair growth and anti-hair loss effects; a hair follicle-targeting molecule capable of specifically recognizing and binding to receptors on the surface of hair follicle cells; and a targeting and anchoring conjugate consisting of a linker covalently linked to the hair follicle-targeting molecule and an anchoring lipid. The targeting and anchoring conjugate is embedded in the lipid bilayer of the lipid nanoparticle core via the anchoring lipid, thereby exposing the hair follicle-targeting molecule on the surface of the lipid nanoparticle core. This application, through its innovative targeting and anchoring conjugate structure, can significantly improve the targeting and enrichment efficiency of the hair growth and anti-hair loss active ingredients on hair follicle tissue, ensuring precise drug action on the lesion site, thereby significantly increasing the number of hair follicles in the alopecia areata modeling area.

The present invention relates to compositions comprising nucleic acid-lipid particles, wherein the nucleic acid-lipid particles are characterized by encapsulation of the nucleic acid in a lipid bilayer. The present invention further relates to said compositions for use in preventing and / or treating disease, particularly for use in preventing and / or treating cancer. The present invention further relates to methods for producing compositions comprising said nucleic acid-lipid particles.

A computational system and method for digital modeling of cardiac cell membrane electrophysiology is disclosed. The system generates a digital model representing the cell membrane as a dielectric lipid bilayer comprising a capacitor element and a resistor element, where the resistor element is emulated by a plurality of ion channels. The system calculates cell membrane potential based on intracellular and extracellular concentrations of key ions, such as Na+, K+, Ca2+, and Cl-, using the Goldman-Hodgkin-Katz equation. Generation of cellular membrane action potentials is simulated by modeling the opening and closing of voltage-gated ion channels in response to triggering events. The model provides dynamic visualizations of the distinct phases of the action potential, including depolarization and repolarization, offering a high-fidelity tool for research and for enhancing the realism of training simulations in electrophysiology procedures.

This invention belongs to the field of cosmetic technology and discloses an anti-wrinkle essence containing Panax notoginseng oil and its preparation method. The essence comprises Panax notoginseng oil, phospholipids, a membrane flexibility regulating component, tocopheryl acetate, a polyol moisturizer, xanthan gum, carbomer, a pH adjuster, a preservative system, and water. The Panax notoginseng oil, phospholipids, the membrane flexibility regulating component, and tocopheryl acetate together constitute a flexible nanoliposome dispersion system. Panax notoginseng oil, as a functional oil phase, participates in the lipid bilayer construction and is dispersed in the aqueous essence system in a structured encapsulation form. Tocopheryl acetate exists in the flexible nanoliposomes as a membrane stabilizing component and an oil phase antioxidant protective component. The preparation method includes preparing the aqueous phase of the essence matrix, preparing a lipid phase premix containing Panax notoginseng oil, dropwise adding it to form an initial dispersion and homogenizing under high pressure, vacuum degassing, and adjusting the pH to obtain the finished product. This essence exhibits good dispersion stability, strong antioxidant capacity, and good anti-wrinkle effects.

The present application provides a method for preparing a liposome composition. In the method, a containing step is provided, including: providing precursor liposomes wrapping a platinum drug precursor; and culturing the precursor liposomes in a salt solution to convert the platinum drug precursor into a platinum drug to obtain the liposome composition. The precursor liposomes are obtained by the following steps: hydrating the platinum drug to obtain the platinum drug precursor; and adding the platinum drug precursor to a lipid bilayer carrier to obtain the precursor liposomes. The liposome composition prepared by the method has better coating rate and stronger drug loading capacity.

Provided is a viral vector having a lipid bilayer envelope, the lipid bilayer envelope comprising an antibody binding domain displayed outside the envelope, the antibody binding domain being cell type specific; a viral envelope protein exhibited outside the envelope, the viral envelope protein being capable of promoting infection of the same cell type; and a nucleic acid molecule comprising a promoter capable of being expressed in the same cell type. Methods of making the viral vectors and methods of modifying cells and treating diseases / conditions using the viral vectors are also provided.

The invention relates to the technical field of skin care, and discloses a sustained-release composition containing azelaic acid composite lipidosome and application of the sustained-release composition in acne treatment and skin repair. Comprising a composite liposome, an encapsulated active component and a dispersion medium, the composite liposome is composed of a lipid bilayer, the lipid bilayer comprises phospholipid, cholesterol and pegylated phospholipid, and the phospholipid is a mixture of hydrogenated soybean phospholipid and dipalmitoyl phosphatidylcholine; the encapsulated active component comprises a fat-soluble component and a water-soluble component; the water-soluble components comprise a hamamelis virginiana leaf water extract and a herba portulacae extract; the dispersion medium is a phosphate buffer solution; by optimizing lipid composition, introducing surface modification and constructing a multi-layer release system, the invention aims to synergistically exert multiple effects of antibiosis, anti-inflammation, cutin regulation, red fading, repair and the like, and provides an efficient, mild and integrated solution for acne and sequelae skin problems thereof.

Disclosed are: a fluorescent compound represented by general formula (I), (I)′, or (I)″, as a fluorescent compound which has high retention in a lipid bilayer, has excellent ease of handling, and can achieve uniform dyeing in a dyeing target; and a lipid bilayer dyeing method and an endocytosis detection method using said compound.Ch is a hydrophobic-field-sensitive fluorescent chromophore in which the fluorescence intensity increases in hydrophobic environments; A-H is an anionic functional group capable of generating anions by deprotonation; Xn+ is a positive ion having biological compatibility; n is 1, 2, or 3; L is a linker that binds to a hydrophobic-field-sensitive fluorescent chromophore and links the fluorescent chromophore and the anionic functional group; and LH+ indicates a state wherein the linker, which contains a cationic functional group capable of generating cations by protonation, has generated a cation by protonation.

Drug-loaded microbead compositions include microbeads of a water-swellable polymer material and a complex of a carrier and a therapeutic agent chemically bonded to the carrier. The complex is embedded in the polymer material. Methods for preparing the drug-loaded microbead compositions and embolization compositions include loading a therapeutic agent into a water-swellable polymer material to form microbeads, then removing water from the microbeads. Additional drug-loaded microbead compositions include microbeads of a biodegradable material, vesicular agents, a first therapeutic agent associated with the vesicular agents, and a second therapeutic agent different from the first therapeutic agent. The vesicular agents include a lipid bilayer surrounding a vesicular core. The second therapeutic agent is contained within the microbeads or associated with the microbeads through ionic or non-covalent interaction and may or may not be associated with the vesicular agents. Drug-loaded biodegradable microbead compositions include microbeads of biodegradable material and a therapeutic agent.

The application discloses multimeric assemblies including multiple oligomeric substructures, where each oligomeric substructure includes multiple proteins that self-interact around at least one axis of rotational symmetry, where each protein includes one or more polypeptide-polypeptide interface (“O interface”); and one or more polypeptide domain that is capable of effecting membrane scission and release of an enveloped multimeric assembly from a cell by recruiting the ESCRT machinery to the site of budding by binding to one or more proteins in the eukaryotic ESCRT complex (“L domain”); and where the multimeric assembly includes one or more subunits comprising one or more polypeptide domain that is capable of interacting with a lipid bilayer (“M domain”), as well as membrane-enveloped versions of the multimeric assemblies.

The invention discloses a quercetin nano-vesicle complex as well as a preparation method and application thereof. The preparation method of the nano-vesicles comprises the following steps: separating and purifying extracellular vesicle-like nano-particles from cow milk by combining differential centrifugation with an EDTA precipitation method; quercetin is efficiently loaded in a vesicle nanostructure by adopting an ultrasonic-assisted co-incubation technology, and a drug loading system is characterized through particle size analysis, Zeta potential determination and a transmission electron microscope. The natural lipid bilayer structure of the milk-derived extracellular vesicles is creatively utilized, the constructed quercetin nano-vesicle complex shows excellent stability in simulated gastrointestinal fluid, and the average encapsulation efficiency can reach 60%. In-vitro and in-vivo experiments prove that the nano vesicles can efficiently remove senescent cells. The invention has a wide clinical application prospect in the field of anti-aging and inflammation-related disease treatment.

The application relates to a kind of lipid nanocarriers coupled with GO-203 and loaded with DMAMCL and its preparation method and application, belong to the field of biological medicine and nano-preparation.The lipid nanocarriers include water phase core, lipid bilayer and surface modification layer from inside to outside, wherein water-soluble dimethylamine methyl chloride (DMAMCL) is loaded in the water phase core;The lipid bilayer is wrapped in the water phase core, and coumarin-6 is embedded as fluorescent marker for tracing and detection;Functional modification layer is arranged on the outer surface of the lipid bilayer, including DSPE-PEG2000-COOH and DSPE-PEG2000-GO-203, wherein GO-203 is cell membrane penetrating peptide.The lipid nanocarrier provided by the application can realize the synergistic delivery of GO-203 and DMAMCL, be used for regulating tumor immune microenvironment and be used for the treatment of triple-negative breast cancer.

The exosome-glucan compound preparation provided by the invention comprises a stem cell exosome, the final concentration of the stem cell exosome in the exosome-glucan compound preparation is 1 * 10 < 8 > parts / mL to 1 * 10 < 12 > parts / mL based on particle concentration quantification or 1 mu g / mL to 500 mu g / mL based on exosome total protein quantification, and the final concentration of the stem cell exosome in the exosome-glucan compound preparation is 1 * 10 < 8 > parts / mL to 1 * 10 < 12 > parts / mL based on particle concentration quantification or 1 mu g / mL to 500 mu g / mL based on particle concentration quantification. The dextran is used as a matrix entrapment stem cell exosome, the weight-average molecular weight of the dextran is 10kDa to 5000kD, and the weight / volume percent of the dextran in the exosome-dextran compound preparation is 0.5% to 20%; glucan is used as a biocompatible matrix, and a lipid bilayer structure of the glucan wraps the stem cell exosome to form a physical protection barrier, so that the stem cell exosome is prevented from being degraded and inactivated in an in-vitro storage or in-vivo complex environment; and the degradation rate of the glucan matrix is matched with the wound healing period, so that long-acting slow release of the exosome is realized, and the bioavailability of a focus part is improved.

Articles, compositions, kits, and methods relating to nanostructures, including synthetic nanostructures, are provided. Certain embodiments described herein include structures having a core-shell type arrangement; for instance, a nanostructure core may be surrounded by a shell including a material, such as a lipid bilayer, and may include other components such as oligonucleotides. In some embodiments, the structures, when introduced into a subject, can be used to deliver nucleic acids and / or can regulate gene expression. Accordingly, the structures described herein may be used to diagnose, prevent, treat or manage certain diseases or bodily conditions. In some cases, the structures are both a therapeutic agent and a diagnostic agent.

The invention provides a lipidosome adjuvant system based on furanose type QS-21 saponin molecules and a preparation method. The lipidosome adjuvant system comprises lipidosome and the QS-21 saponin molecules, the lipidosome comprises a lipid bilayer formed by ionizable lipid, structural phospholipid and cholesterol, the QS-21 saponin molecule is in a furanose type and is loaded on the lipidosome, and the QS-21 saponin molecule is partially inserted into the lipid bilayer through hydrophobic triterpenoid aglycone of the QS-21 saponin molecule. The preparation method comprises the following steps: dissolving lipidosome components forming lipid bilayers in an organic solvent to form a lipid phase, dissolving furanose type QS-21 saponin molecules in an acidic aqueous phase buffer solution to form a QS-21 aqueous phase, mixing the lipid phase and the QS-21 aqueous phase, precipitating lipid, and self-assembling to form lipidosome nanoparticles loaded with furanose type QS-21 saponin molecules, and finally, purifying to remove the organic solvent and the unencapsulated QS-21 molecules. According to the invention, through well-designed lipid composition and a preparation process, furanose type QS21 molecules are stably integrated into the lipidosome.

The invention discloses a quintuple VC (Vitamin C) nano-liposome composition and a preparation method thereof. The composition has a unique core-shell structure, wherein an inner core of the composition is a stable compound formed by a quintuple VC active system extracted through biological fermentation of kiwi fruits and cationic polysaccharide through electrostatic interaction; and the shell is a lipid bilayer membrane formed by self-assembly of phospholipid, cholesterol and a glycoside surfactant. The quintuple VC active system is a synergistic system and comprises five functional components including prototype VC, a VC derivative, a VC endogenous synthesis precursor, a VC natural protective agent and a VC penetration enhancer. The core of the preparation method is as follows: firstly, a VC-polysaccharide compound nano dispersion is prefabricated through a microjet technology to serve as an inner core; injecting the warm W / O type colostrum into a low-temperature bulk water phase by utilizing a temperature difference triggering type self-assembly technology, and instantaneously triggering lipid to encapsulate the inner core to form the nano-liposome; and finally, carrying out continuous purification and concentration through online tangential flow ultrafiltration.

A method of treating Parkinson's disease in a subject in need thereof. The method comprises administering a liposomal composition, comprising sphingomyelin in a lipid bilayer and a therapeutically effective amount of GM1, to the subject.

Disclosed herein is a modified oligonucleotide, the modified oligonucleotide comprises one or more modifications in at least one of a phosphate backbone, a nucleobase, or a sugar. The one or more modifications impede translocation through a nanopore by increasing non-covalent interactions with the interior of the nanopore or the lipid bilayer that supports the nanopore, increasing the bulk size or the steric hinderance of oligonucleotide, or alter the charge density of the oligonucleotide.

Provided is a membrane permeation promoter that promotes permeation of a conjugate of a target substance and a transmembrane peptide into a lipid bilayer membrane, the membrane permeation promoter containing a flavonoid. Also provided are a membrane permeation promoting method and intracellular delivery method using the membrane permeation promoter, and an intracellular delivery kit comprising the membrane permeation promoter.

Nucleic acid immunization is achieved by administering RNA encapsulated within a liposome. The RNA encodes a relevant immunogen, and the liposome has a diameter in the range of 60-180nm, and ideally in the range of 80-160nm. Accordingly, the invention provides a liposome having a lipid bilayer encapsulating an aqueous core, wherein: (i) the lipid bilayer has a diameter in the range of 60-180nm; and (ii) the aqueous core comprises an RNA encoding an immunogen. These liposomes are suitable for in vivo delivery of the RNA to a vertebrate cell and are thus useful as components in pharmaceutical compositions for immunizing subjects against various diseases.

The application discloses a kind of targeted delivery molecules, particle and its preparation method, application, comprising the following steps: step 1: to the polyethylene glycol molecule A solution containing maleimide group and hydrophobic group is added dropwise with thiol-containing polypeptide targeting factor B solution, stir and react fully;Wherein the amount-of-substance ratio of A and B is 1:1;Step 2: the solution obtained in step 1 is dialyzed, freeze-dried to obtain the required targeted delivery molecules;The targeted delivery molecules prepared by the application have cartilage cell-specific polypeptide targeting factor at one end, and can target cartilage tissue.The hydrophobic group at the other end can be inserted into the hydrophobic lipid bilayer by physical action.The polypeptide targeting factor is assembled on the surface of cell, cell exosome, liposome and other vesicles composed of lipid bilayer, which has the effect of treating osteoarthritis.The above-mentioned cells and vesicles can be targeted to deliver the contents to cartilage, and have good application prospect in the treatment of osteoarthritis.

A transdermal patch for delivering lidocaine for pain relief comprises a backing layer, an adhesive layer, and a composition containing lidocaine in an amount ranging from about 1% to about 10% by weight and heparin as a non-anticoagulant permeation enhancer in an amount ranging from about 1% to about 50% by weight. The heparin enhances permeation of lidocaine through the skin without exerting systemic anticoagulant effects by temporarily disrupting lipid bilayers in the stratum corneum to create microchannels for increased diffusion of lidocaine molecules. The patch provides effective relief for multiple pain types including neuropathic pain, inflammatory pain, ischemic pain, post-surgical pain, nociplastic pain, mechanical pain, and compressive pain. The transdermal patch is configured to provide sustained release of lidocaine for periods ranging from about 8 hours to about 24 hours, reducing pain by at least 50% with minimal systemic absorption.

A viral vector having a lipid bilayer envelope is provided, comprising a cell-type specific antibody-binding domain presented outside the envelope, a viral envelope protein presented outside the envelope capable of promoting infection of the same cell type, and a nucleic acid molecule containing a promoter expressible in the same cell type. Furthermore, a method for producing the viral vector and a method for modifying cells and treating diseases / conditions using this viral vector are also provided.

This invention discloses a dual-targeting DNA vaccine delivery system based on calcium phosphate lipid nanoparticles, belonging to the field of biomedicine. The delivery system comprises calcium phosphate containing histone H1 and an HPV E6 / E7 fusion gene plasmid, and a lipid bilayer membrane of DSPE-PEG-2000-Mannose. This system achieves targeted uptake by dendritic cells through mannose modification and relies on histone H1-mediated DNA nuclear transport. The dual targeting significantly enhances antigen expression efficiency. In vitro and in vivo experiments have demonstrated that this delivery system exhibits good biocompatibility and high stability, effectively activating antigen-specific T-cell immune responses, and possesses both HPV infection prevention and cervical cancer treatment effects, providing a new strategy for cervical cancer prevention and treatment.

Provided herein is a method of ameliorating muscle loss in a subject induced from the treatment of the subject with a GLP-1 agonist with the administration to the subject of a therapeutically effective amount of a placenta derived biological material having a continuous lipid bilayer membrane